http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Intrexon (XON) Appoints Helen Sabzevari, PhD, as New President and CEO, to Change Name, Sell Non-healthcare Assets
-
Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus
-
Intrexon (XON) Subsidiary, Triple-Gene LLC, Reports Prelim. Ph. 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure
-
Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting
-
Intrexon Reports Third Quarter 2019 Financial Results
-
UPDATE: Intrexon (XON) Subsidiary Triple-Gene LLC Reports Complete Enrollment & Dosing in Ph. 1 Trial of INXN-4001
-
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
-
Intrexon to Announce Third Quarter Financial Results on November 12th
-
David H. Witte to lead MBP Titan LLC
-
Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli™ Cannabis Plantlet Production
-
Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli™ Cannabis Plantlet Production
-
Intrexon (XON) Subsidiary ActoBio Therapeutics Grantef IND Green Light for New Antigen-Specific Immunotherapy Study
-
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
-
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
-
Intrexon Reports Second Quarter and First Half 2019 Financial Results
-
Intrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosing in Phase 1 Study of PRGN-3005 UltraCAR-T
-
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
-
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th
-
Intrexon (XON) Subsidiary ActoBio Therapeutics Inc. Advances AG019 to Next Stage of Phase Ib/IIa Clinical Study
-
ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
-
Intrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T
-
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
-
Intrexon (XON) and Surterra Wellness announce exclusive global licensing agreement
-
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
-
Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
-
Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology
-
Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce
-
Fibrocell Science (FCSC) Granted FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for Treatment of RDEB
-
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
-
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
-
Intrexon to Participate in 2019 BIO International Convention
-
Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
-
Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
-
Intrexon Reports First Quarter 2019 Financial Results
-
Intrexon to Release First Quarter 2019 Financial Results on May 9th
-
Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting
-
Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland
-
Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper
-
Fibrocell Science (FCSC) Announces Pact with Castle Creek Pharma to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
-
Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference
-
Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development
-
Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
-
Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management
-
Fibrocell Science (FCSC) Reports Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
-
Intrexon and Surterra Wellness to Collaborate on Botticelli™ Next Generation Plant Propagation for Cannabis Cultivation
-
Intrexon Reports 2018 Fourth Quarter and Year End Financial Results
